. 2025 Mar 11;39(5):407–423. doi: 10.1007/s12149-025-02022-x

Table 6.

Comparison between FAPI-X PET/CT and [¹⁸F]FDG PET/CT evidence for each clinical application in sarcomas

Sarcomas
Degree of Radiopharmaceutical Uptake	Higher uptake in low-grade sarcomas (10.4 ± 8.5, p = 0.01) [87]	Lower uptake in low-grade sarcomas (7.0 ± 4.5, p = 0.01) [87]
Radiopharmaceutical therapy	Promising results [⁹⁰Y]-FAPI-46 and [¹⁷⁷Lu]Lu-FAPI-2286 Safety treatment with low adverse effects (mainly laboratory findings) [88, 89]	N/A

Sarcomas

Application

FAPI-X

[¹⁸F]FDG

Degree of Radiopharmaceutical Uptake

Higher uptake in low-grade sarcomas (10.4 ± 8.5, p = 0.01) [87]

Lower uptake in low-grade sarcomas (7.0 ± 4.5, p = 0.01) [87]

Radiopharmaceutical therapy

Promising results [⁹⁰Y]-FAPI-46 and [¹⁷⁷Lu]Lu-FAPI-2286

Safety treatment with low adverse effects (mainly laboratory findings) [88, 89]

N/A

FAPI-X: FAPI-X PET/CT; [¹⁸F]FDG: [¹⁸F]FDG PET/CT; N/A: not applicable; Uptake: Degree of Radiopharmaceutical Uptake; T: tumour; N: nodes; M: metastases